Evaluation of Drug Pricing Regulation Policies within Colombian Health Expenditure, 2010-2017

Oscar Espinosa Acuña, Hernan Enriquez (), Diego Ávila, Sergio Basto, Daniela Rivera, Daniela López, Paola Avellaneda and Paola Riveros

Journal of Economic Issues, 2022, vol. 56, issue 3, 805-819

Abstract: This research presents the impact assessment for medication price regulation policy in Colombia, having as a frame of reference the relevant markets and the Unique Code of Medicines (CUM) [Código Único de Medicamentos], regulated in the circulars 04, 05, 06, 07 of 2013, and 01 of 2014. After an interdisciplinary construction of a database with information between 2010 and 2017, a statistical model of dynamic difference-in-differences was estimated. Although the effect is momentary, the reduction of spending, as an objective of the policy, it is notorious. This behavior mainly occurs since most of the medicines included in regulation reflect monopoly prices, where the most significant reduction in prices was observed and, therefore, the most considerable expense restraint.

Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1080/00213624.2022.2093574 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:mes:jeciss:v:56:y:2022:i:3:p:805-819

Ordering information: This journal article can be ordered from
http://www.tandfonline.com/pricing/journal/MJEI20

DOI: 10.1080/00213624.2022.2093574

Access Statistics for this article

More articles in Journal of Economic Issues from Taylor & Francis Journals
Bibliographic data for series maintained by Chris Longhurst ().